Recent

% | $
Quotes you view appear here for quick access.

Red Hat, Inc. Message Board

green_side_up 371 posts  |  Last Activity: Dec 16, 2015 3:19 PM Member since: Nov 2, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Omerycuss21 is doing his best to scare you all by posting non-stop about .60, .50, .40, .30. That is #$%$. Go to the 10-Q, look at all the potential warrants and options outstanding, and calculate the valuation. We're talking

    Sentiment: Strong Buy

  • Reply to

    Unrealistic SP

    by poise2viscosity Dec 9, 2015 2:19 PM
    green_side_up green_side_up Dec 9, 2015 3:16 PM Flag

    When calculating Cash / Share, you can't remove the Roche shares...you have to use fully-diluted shares outstanding.

  • Reply to

    Some issues concern me

    by green_side_up Jul 20, 2015 12:45 PM
    green_side_up green_side_up Jul 20, 2015 12:56 PM Flag

    Also, CYDY has to give 12.5% of royalties to former owners of Pro 140 including Abbvie, who walked away from the drug. That's A LOT for nothing. Usually you give up something to get something. There is no partnership here. A partner would provide manufacturing, distribution and marketing help. So, that's a lot of potential revenue off the table for nothing.

    It all doesn't quite add up.

  • green_side_up by green_side_up Jul 20, 2015 12:45 PM Flag

    1) Dilution is ongoing...only raised $2 million out of $30 million needed with a reverse stock split imminent barring a major increase in share price. This is a red flag.
    2) The Chairman of the Board at CYDY used to work for years at Gilead - he could either fund a portion of the capital raise himself - if he truly thought the Pro-140 technology was such a game changer as he knows the cocktails of HIV drugs probably better than anyone - or he should know everyone you would need to know in biotech in order to raise capital with a strong investor group. This is a red flag, as CYDY should not be having issues with uplisting requirements or with funding if the Pro 140 was such a game changer.
    3) Gilead - Why hasn't Gilead knocked on the door...they have the most to lose in the drug cocktail area and its former Chairman is now the CYDY Chairman...there is a disconnect here. Another red flag.
    4) CamImmune and others are indeed working on single shot gene therapies for HIV. While Pro-140 is more advanced, it doesn't deal with all the potential strains of HIV, and it could be trumped by any gene therapy showing efficacy in early stage trials. That's a Red Flag and a big risk for investors.
    5) Monotherapy data puzzles me: Results from the initial 14-week treatment substitution monotherapy trial (which excludes viral load failures due to patient screening errors) were as follows:
    98% of the patients passed 4 weeks of monotherapy
    91% of the patients passed 6 weeks of monotherapy
    82% of the patients passed 8 weeks of monotherapy
    70% of the patients passed 11 weeks of monotherapy (maximum allowable monotherapy without an extension study)
    14 patients, who were offered to continue in an extension study with this monotherapy, are approaching 6 months without experiencing a viral load rebound. We know some of these 14 patients have shown 11-months of no viral load, which is great, but 30% patients did not pass. Again, not as strong as it could be...

    Sentiment: Hold

  • green_side_up by green_side_up Jan 27, 2015 10:41 AM Flag

    Leo pumping the stock again based on government initiatives. I mean, come on Leo...you can do A LOT better than that. This guy is a fantastic...not just a fool...but a fantastic fool. He is a pumper...plain and simple. How can you not see it with this press release? It's a joke, by an OTC listed stock where the founders own a lot of shares. And, recall, how Leo and Menon finally capitulated and granted stock to the other CTIX founder, who they pushed aside initially. These guys are so shady.

    Leo cherry-picks one Kevetrin patient who did so well that the patient had to leave the trial...LOL! CTIX buys Polymedix for $5 million and says it's just as good, if not better, than Cubist's billion dollar drug. I guess the Polymedix shareholders thought the same thing before it went bankrupt. And, clearly Merck was laughing when it did its research on the antibiotic market and bought Cubist instead of buying CTIX (and also getting this amazing Kevetrin and Prurisol) for 15x less. Oh by the way, Novartis just got approval for their highly effective anti-psoriasis drug the other day.

    Be very careful owning CTIX...look for dilution soon. These hospital systems are not charity organizations. They are not going to run advanced trials for free. There are no partnerships coming.

    Take your emotions out of the stock and just follow the stock promotion very closely.

    Sentiment: Strong Sell

  • Reply to

    upgrades coming ..that data was great

    by bkfviking123 Jan 26, 2015 10:51 AM
    green_side_up green_side_up Jan 26, 2015 3:11 PM Flag

    Wasn't the data based on only 1 patient? Patient 1 data seemed to be very good, but patient 2 data didn't seem good to me, unless I'm missing something. I think HTBX has potential, but you have to see the full study data to determine safety and efficacy. I feel like this data was cherry-picked.

  • Reply to

    So MRK buys CBST instead of CTIX, hmmmm????

    by green_side_up Dec 8, 2014 9:21 AM
    green_side_up green_side_up Dec 8, 2014 9:29 AM Flag

    Fraz, the big money goes wherever the drug development takes them. Absolutely ZERO difference if its in the Pink Sheets or its Privately Owned. Nice spin job. Do you think MRK shareholders care if MRK buys a Pink Sheet stock if it's a blockbuster? Again, nice spin job Fraz! LOL

    CTIX certainly deserves to be on the Pinks.

  • I can't wait to hear what Leo and this message board says about this deal. When you spend $8 billion+, you can bet that the Merck team made sure that CBST drug was not going to fall off a cliff to the competition. Clearly, Merck does not think that Brilacidin is a real threat. Otherwise, why not buy CTIX and get access to the amazing Kevetrin and incredible Prurisol too?

    Sentiment: Strong Sell

  • green_side_up green_side_up Nov 17, 2014 5:08 PM Flag

    Lee...you are funny. CBST's EV is $5.5 billion...have fun with your CTIX dilution.

  • green_side_up green_side_up Nov 17, 2014 1:40 PM Flag

    The point is that CBST could have acquired CTIX instead

  • Cubist Pharmaceuticals is investing significantly in global antibiotic R&D and is focusing its late-stage pipeline on addressing serious and potentially life-threatening healthcare-acquired bacterial infections. To fight the global battle against antibiotic resistance and to support the potential launch of two new antibiotics in Europe in 2015, Cubist is expanding its presence in Europe and has recently begun operations in the UK. Cubist expects to invest approximately $400M in 2014 on antibacterial R&D and hopes to deliver at least four new antibiotics in support of the Infectious Diseases Society of America goal of 10 new antibiotics by 2020.

    Conclusion: CBST sees zero value in the CTIX antibiotic drug

    Sentiment: Strong Sell

  • Reply to

    Where's the Secondary?

    by eqivacation Nov 13, 2014 7:23 AM
    green_side_up green_side_up Nov 14, 2014 10:37 AM Flag

    Well, they are burning through $1 million per quarter and have only $1 million left, so some type of financing has to be imminent. But, there has been some progress in the business. Yet, I would wait until there's more clarity on financing before buying the stock.

  • Nice report.

    FYI, for those who don't know how Wall Street works, on the earnings, you have to add back the non-cash expenses.

  • Reply to

    AccessWire

    by green_side_up Nov 12, 2014 12:16 PM
    green_side_up green_side_up Nov 12, 2014 1:03 PM Flag

    Whenever I see these articles, I try to keep in mind Adam Feuerstein's articles on GALE and their use of The DreamTeam Group to pump up their stock. Like I said, just be careful.

    Sentiment: Strong Sell

  • green_side_up by green_side_up Nov 12, 2014 12:16 PM Flag

    Don't you love when micro and small cap companies pay a 3rd party some type of compensation to issue press releases to tout their developments. Such a conflict of interest.

    Leo is likely trying to increase the stock price to try to limit the dilution from the shelf registration.

    The data should speak for itself.

    Buyer beware.

    Sentiment: Strong Sell

  • Reply to

    Latest pr

    by fudruckker Nov 11, 2014 8:08 AM
    green_side_up green_side_up Nov 11, 2014 9:48 AM Flag

    "After discussion with FDA later this year, Cellceutix plans to disclose additional information regarding the Phase 2b trial results."

    Why does CTIX need to discuss with the FDA before disclosing Phase 2b trial details?

    Seems strange to me and sounds like a potential Red Flag

  • Reply to

    There is no way to sugercoat this--

    by cmblanch1 Nov 5, 2014 12:34 PM
    green_side_up green_side_up Nov 7, 2014 11:03 AM Flag

    Why wouldn't you wait until more data comes out on any of the three major drugs before announcing a shelf offering? Take Regulus (RGLS), they announced a follow-on offering, at $18-$20 after releasing strong Hepatitis-C data for their RNA drug. The stock was trading at $7-$8 before the announcement. CTIX did not move on the Phase 2b data for Brilacidin. They clearly need the funds to run these 5 clinical trials and don't want to wait for what could be better received news - and thus, we have far greater dilution for existing shareholders.

  • Reply to

    Stock is crashing

    by lee1220neill Nov 4, 2014 2:32 PM
    green_side_up green_side_up Nov 7, 2014 12:18 AM Flag

    Frank, you maybe 100% correct.

  • Reply to

    Stock is crashing

    by lee1220neill Nov 4, 2014 2:32 PM
    green_side_up green_side_up Nov 6, 2014 7:19 PM Flag

    Here's a good example of a Phase 2b trial for the exact same ABSSSI indication done in December 2011 by Melinta Therapeutics comparing their drug to vancomycin. See link:

    http://melinta.com/dev/topic16.php

    Here's the kay point: "Of note, for the primary endpoint of Investigators’ Global Assessment of Cure, delafloxacin demonstrated statistical superiority in comparison to vancomycin (95% Confidence Interval -30.3%, -2.3%; p=0.031)."

    The low p-value gives conviction to the comparison data, something that CTIX did not provide in its press release, but I think will be disclosed in April 2015.

    By the way, this drug, as seen in the link below, just entered Phase 3 trials in May 2014, showing you how long it can take to develop drugs. (Note, I don't know the history of this company in terms of financing and other pipeline priorities or any issues with Phase 3 protocol. It's just an example)

    http://www.reuters.com/article/2014/05/05/idUSnGNX8f6Dd4+1c4+GNW20140505

  • Reply to

    Stock is crashing

    by lee1220neill Nov 4, 2014 2:32 PM
    green_side_up green_side_up Nov 6, 2014 4:01 PM Flag

    Cellceutix is preparing a poster on the completed Phase 2b clinical trial for presentation at the 25th European Congress of Clinical Microbiology and Infectious Diseases, which will be held from April 25 - 28, 2015 in Copenhagen, Denmark.

    Lee - stop the badgering...being mean is bad karma, it's why you're losing your profits.

RHT
63.14-5.48(-7.99%)Feb 5 4:02 PMEST